Geode Capital Management LLC Acquires 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX)

Geode Capital Management LLC grew its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC’s holdings in Quince Therapeutics were worth $263,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

QNCX has been the topic of a number of research reports. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Maxim Group initiated coverage on Quince Therapeutics in a research report on Thursday, November 7th. They set a “buy” rating and a $6.00 price objective on the stock. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, D. Boral Capital restated a “buy” rating and set a $12.00 price objective on shares of Quince Therapeutics in a research report on Thursday, January 2nd. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $9.50.

Quince Therapeutics Stock Down 3.4 %

Shares of QNCX opened at $1.73 on Tuesday. The company has a market capitalization of $76.12 million, a PE ratio of -1.40 and a beta of 0.64. Quince Therapeutics, Inc. has a 12 month low of $0.51 and a 12 month high of $2.45. The stock’s 50-day moving average price is $1.86 and its two-hundred day moving average price is $1.16. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.